1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
Biosimilars: Global Markets

Biosimilars: Global Markets

  • January 2015
  • 136 pages
  • ID: 919318


Table of Contents


The global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014. The market is expected to reach nearly $4.0 billion by 2019, with a compound annual growth rate (CAGR) of 15% from 2014 through 2019.

This report provides:

An overview of the global market for biosimilars.
Analyses of global market trends, with data from 2012 through 2014, and projections of CAGRs through 2019.
A look at biosimilar product classes in various regions worldwide, as well as the worldwide pipeline for biosimilars.
Detailed analysis of the emerging regulatory framework in regulated markets as well as comparisons of biosimilar guidelines in Europe, the U.S., Japan, Canada, and the guidelines developed by WHO.
Technology trends and patent analysis.
Comprehensive profiles of key players in the market.


Biosimilars are an affordable alternative to well-established therapeutic interventions. Biosimilars are similar to but not identical copies of the already approved biologics. BCC Research’s goal in conducting this study is to provide an overview of the current and future characteristics of the market for biosimilars. The key objective is to present
a comprehensive analysis and future direction of biosimilars. Present and future approaches within the biosimilars market are investigated in this report. For the purpose of this report, the biosimilars market is categorized into, erythropoietins, human growth hormone (HGH), granulocyte colony-stimulating factors (G-CSF), low-molecular-weight heparins (LMWH) and other biosimilars. The improvisations of the market, and the setbacks and the needs of the market are discussed in this report. Current market trends for biosimilars are also reported. A thorough analysis of the structure of the biosimilar industry is provided. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2014 through 2019. The report also covers significant patents and their allotments in each category.


In recent years, significant changes in the regulatory aspects of biosimilars plus their cost effectiveness are driving new energy in the biosimilars market. Even though the market is in its infancy, opportunities are set to expand as patents expire on leading biologics. This is pointing the way for accelerated market growth. An increasingly aging population, growth in chronic illness and expanding need for healthcare worldwide will help drive the growth of biosimilars over the next few years, especially due to their affordability.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each type/market in light of new technologies, growing competition and changing customer needs.


The scope of this study encompasses biosimilars in pharmaceutical and biotechnology markets. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections, and market shares.
In semi- and unregulated markets, various copies of biologics were sold for many years before the establishment of biosimilar guidelines by the European Medicines Agency (EMA). The regulatory processes are considerably less stringent in less regulated markets as compared to that of EMA; hence, a number of biosimilars are available in these regions. However, manufacturers are now targeting regulated markets, and are adopting various strategies to enter highly regulated markets such as Europe and the U.S. Therefore, the report includes all the products for which EMA has already published guidelines for market authorization or for which guidelines are under development.
This report includes product segments such as somatropin, erythropoietin, colony-stimulating factors (CSFs), interferons, interleukins, insulin and insulin analogues, follicle-stimulating hormones (FSHs), monoclonal antibodies (MAbs) and low-molecular-weight heparins (LMWHs). This report is a comprehensive study on the demand for biosimilar drugs that have entered the market worldwide. Technological issues include the latest trends and developments.
The emerging markets for biosimilars include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Clinical Trial Strategies in Biosimilar Drug Development

Clinical Trial Strategies in Biosimilar Drug Development

  • $ 10000
  • Industry report
  • October 2017
  • by Datamonitor Healthcare

As the patent cliff for many blockbuster biologic therapies is approaching, clinical development programs for biosimilar options to those therapies are emerging at a rapid pace. Among the key areas of ...

Insulin Biosimilars - Global Market Outlook (2017-2023)

Insulin Biosimilars - Global Market Outlook (2017-2023)

  • $ 3662
  • Industry report
  • November 2017
  • by Stratistics MRC

Stratistics MRC, are pleased to announce the latest publication of Global Insulin Biosimilars market. Growing pervasiveness of type 1 diabetes and ongoing approvals by the government authorities are nurturing ...

Commercialisaton of Biosimilars: Multifunctional teamwork for success

Commercialisaton of Biosimilars: Multifunctional teamwork for success

  • $ 2448
  • Industry report
  • November 2017
  • by Firstword Pharma

Commercialisation of BiosimilarsFrom bench to bedside, biosimilars continue to dominate boardroom discussions around the world. But after all the talking, what’s the secret to success in this high stakes ...


Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.